403 filings
Page 3 of 21
6-K
fh1s82
2 Jun 22
Replicel Life Sciences Inc. Provides Default Status Update
2:03pm
6-K
057yhwl spy7fv
17 May 22
Replicel Life Sciences Inc. Provides Default Status Update
6:51pm
6-K
lb9zfx9h
10 May 22
Replicel Life Sciences Inc. Announces Application for a Management Cease Trade Order
4:34pm
D
axesma5ihe0kc
10 May 22
$592.73K in equity / options / securities to be acquired, sold $592.73K, 2 investors
3:57pm
NT 20-F
kyk447vvd3
3 May 22
Notice of late annual filing (foreign)
12:15pm
6-K
dculab50cf5s ik
29 Mar 22
RepliCel Announces Non-brokered Private Placement
1:02pm
6-K
hbs5usagpsaf ari5
29 Mar 22
RepliCel Announces Material Patent Milestones
12:51pm
6-K
jl40owo
21 Dec 21
51-102F3 Material Change Report
5:28pm
D
z9qeebr
20 Dec 21
$777.66K in equity, sold $777.66K, 1 investor
12:00am
6-K
bm1epq rw
30 Nov 21
Condensed Consolidated Interim Financial Statements
1:50pm
6-K
7rkzub370nud2i
18 Nov 21
Notice of Annual General and Special Meeting of Shareholders
10:36am
6-K
7fto zved
16 Nov 21
RepliCel’s Clinical Advisory Team Delivers Skin Rejuvenation Clinical Study Synopsis to its Japanese Regulatory and Clinical Study Management Team
4:03pm
6-K
scxhqd8jd 2hrjc
2 Nov 21
RepliCel Announces Dermal Injector Update
12:31pm
6-K
brc6 ets5bmjfmoh
21 Oct 21
Current report (foreign)
3:49pm
6-K
txhofh4
14 Oct 21
51-102F3 Material Change Report
4:00pm
6-K
av5otal7kfhi3 lc1
13 Oct 21
RepliCel Life Sciences Appoints One of Japan’s Foremost Regenerative Medicine Industry Business Leaders as Strategic Advisor
12:00am
6-K
y2vkbbsnk
12 Oct 21
RepliCel and University of Victoria Collaboration Leads to Bioengineering Innovations, Funding, and Patents
1:06pm
6-K
lx77q8rvuoom1xfjbg9
31 Aug 21
Condensed Consolidated Interim Financial Statements
1:45pm
6-K
ubi8le5 ir
18 Aug 21
RepliCel Applies for Manufacturing Approval for its Collagen and Tissue Regeneration Cell Therapies
12:38pm
6-K
1pz5yjoeej5l
18 Aug 21
RepliCel Life Sciences Announces Closing of Debt Settlement
12:34pm